EP1140891A1 - Composes de 1,4-diazacyclo-heptane, procedeede preparation et applications medicamenteuses - Google Patents

Composes de 1,4-diazacyclo-heptane, procedeede preparation et applications medicamenteuses

Info

Publication number
EP1140891A1
EP1140891A1 EP99964753A EP99964753A EP1140891A1 EP 1140891 A1 EP1140891 A1 EP 1140891A1 EP 99964753 A EP99964753 A EP 99964753A EP 99964753 A EP99964753 A EP 99964753A EP 1140891 A1 EP1140891 A1 EP 1140891A1
Authority
EP
European Patent Office
Prior art keywords
alkyl
compound according
formula
compound
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP99964753A
Other languages
German (de)
English (en)
Inventor
Bipinchandra Bhudharlal Chaudhari
Richard Elliot Simon-Bierendaum
Richard Alan Keith
Edward John Warawa
Charles David Mclaren
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of EP1140891A1 publication Critical patent/EP1140891A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Definitions

  • any phenyl ring in R may be optionally substituted, for example by up to five substituents, particularly by up to three substituents which may be the same or different.
  • Typical substituents include: hydroxy; C, 6 alkoxy, for example methoxy; phenylC, 6 alkoxy, for example benzyloxy; mercapto; C, 6 alkylthio, for example methylthio; amino; C, 6 alkylamino, for example methylamino; di-(C, 6 alkyl)amino, for example dimethylamino; carboxy; carbamoyl; C, 6 alkylcarbamoyl, for example methylcarbamoyl; di-C, 6 alkylcarbamoyl, for example dimethylcarbamoyl; C, 6 alkylsulphonyl, for example methylsulphonyl; arylsulphonyl, for example phenylsulphonyl
  • Protecting groups may in general be chosen from any of the groups described in the literature or known to the skilled chemist as appropriate for the protection of the group in question, and may be introduced by conventional methods.
  • a 5 mg/mL of a compound of Formula I is dissolved in an isotonic sterile solution .

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • AIDS & HIV (AREA)
  • Hospice & Palliative Care (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Cette invention a trait à des composés de 1,4-diazacyclo-heptanes correspondant à la formule (I) ainsi qu'à des procédés de préparation de ces composés et à des compositions les contenant. Dans cette formule, R est choisi dans le groupe constitué par de l'hydrogène, un alkyle portant de 1 à 7 atomes de carbone, un alcényle portant de 3 à 8 atomes de carbone, un cycloalkyle portant de 3 à 8 atomes de carbone, un cycloalkyle C3-8 alkyle C1, un phényle C1-6 alkyle et un phényle, à chaque occurrence, R1 est choisi, de manière indépendante, dans le groupe constitué par de l'hydrogène, un alkyle portant de 1 à 6 atomes de carbone, un alcényle portant de 2 à 6 atomes de carbone, un alcoxy portant de 1 à 6 atomes de carbone, un holo, un hydroxy, un alcanoyle portant de 1 à 6 atomes de carbone, un haloalkyle portant de 1 à 6 atomes de carbone, un cyano et un nitro, la valeur de m est de 4, à chaque occurrence, R2 est choisi, de manière indépendante, dans le groupe constitué par de l'hydrogène et un alkyle portant de 1 à 6 atomes de carbone, la valeur de n étant de 4. Ces composés correspondant à la formule (I) sont des plus utiles en pharmacie.
EP99964753A 1999-01-05 1999-12-21 Composes de 1,4-diazacyclo-heptane, procedeede preparation et applications medicamenteuses Withdrawn EP1140891A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9900078.8A GB9900078D0 (en) 1999-01-05 1999-01-05 Chemical compounds
GB9900078 1999-01-05
PCT/GB1999/004351 WO2000040574A1 (fr) 1999-01-05 1999-12-21 Composes de 1,4-diazacyclo-heptane, procedeede preparation et applications medicamenteuses

Publications (1)

Publication Number Publication Date
EP1140891A1 true EP1140891A1 (fr) 2001-10-10

Family

ID=10845530

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99964753A Withdrawn EP1140891A1 (fr) 1999-01-05 1999-12-21 Composes de 1,4-diazacyclo-heptane, procedeede preparation et applications medicamenteuses

Country Status (5)

Country Link
EP (1) EP1140891A1 (fr)
JP (1) JP2003507323A (fr)
AU (1) AU3060500A (fr)
GB (1) GB9900078D0 (fr)
WO (1) WO2000040574A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9914015D0 (en) * 1999-06-17 1999-08-18 Zeneca Ltd Chemical compounds
GB9914025D0 (en) * 1999-06-17 1999-08-18 Zeneca Ltd Chemical compounds
EP1851207B1 (fr) * 2005-02-10 2009-07-01 Neurosearch A/S Nouveaux derives d'homopiperazine substitues alkyle et leur utilisation en tant qu'inhibiteurs du recaptage des neurotransmetteurs de monoamine
CN112375005A (zh) * 2019-08-16 2021-02-19 国药集团工业有限公司 一种氯胺酮、其衍生物或其盐的消旋化方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2064514B (en) * 1979-10-29 1984-01-18 Maruko Pharmaceutical Co Flavan compounds and acid addition salts thereof and pharmaceutical compositions thereof
US4659730A (en) * 1984-06-18 1987-04-21 Eli Lilly And Company Aromatase inhibiting imidazole derivatives
DE3823533A1 (de) * 1988-07-12 1990-02-08 Beiersdorf Ag Substituierte 4-heterocyclyl-2h-benzo(b)pyrane, verfahren und 4-hydroxy-3-brom-, 3,4-oxiranyl-3,4-dehydro-2h-benzo(b)pyrane als zwischenprodukte zu ihrer herstellung, sowie sie enthaltende pharmazeutsche praeparate
FR2687401B1 (fr) * 1992-02-18 1994-05-20 Meram Laboratoires Derives de la 1,4-dialkylpiperazine, procedes d'obtention et compositions pharmaceutiques les contenant.
DE69715865T2 (de) * 1996-07-01 2003-08-07 Schering Corp., Kenilworth Muscarin-antagonisten
CA2226058C (fr) * 1997-01-30 2008-01-29 F. Hoffmann-La Roche Ag Derives de substitution en 8 de 1,3,8-triazaspiro[4.5]decan-4-one

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO0040574A1 *

Also Published As

Publication number Publication date
JP2003507323A (ja) 2003-02-25
WO2000040574A1 (fr) 2000-07-13
AU3060500A (en) 2000-07-24
GB9900078D0 (en) 1999-02-24

Similar Documents

Publication Publication Date Title
DE69513219T2 (de) Kondensierte heterocyclische Verbindungen, ihre Herstellung und Anwendung
US5519019A (en) N-acyl-2,3-benzoidazepine derivatives, pharmaceutical compositions containing them and process for preparing same
EP1389107A1 (fr) Le bisarylimidazolyle, inhibiteur de l'hydrolase des amides d'acides gras
US5639751A (en) N-acyl-2,3-benzodiazepine derivatives for treating acute and chronic neurodegenerative disorders
DE3882679T2 (de) Kardiovaskulaer aktive verbindungen.
US5521174A (en) N-acyl-2,3-benzodiazepine derivatives and a method of treating spasms of the skeletal musculature therewith
US6417183B1 (en) 1,4-diazacycloheptane derivatives
WO2000040574A1 (fr) Composes de 1,4-diazacyclo-heptane, procedeede preparation et applications medicamenteuses
JPH06228112A (ja) （１ｈ，４ｈ）キノキサリン誘導体
US6407093B1 (en) 1,4-Diazacycloheptane derivatives for the treatment of neurological disorders
JPH037280A (ja) 新規ベンゾチオピラニルアミン
EP1192146A1 (fr) Derives du chromane utilises contre les troubles neurologiques
FI66353B (fi) Analogifoerfarande foer framstaellning av terapeutiskt anvaendbara 1-amino-(laegre-alkyl)-3,4-difenyl-1h-pyrazoler
JP2002532475A (ja) １，２，３，４−テトラヒドロナフタレンおよびそれらの薬学的使用
JP3786983B2 (ja) ピロリジノン誘導体
WO2000078736A1 (fr) Derives de 1,4-diazacycloheptane en tant qu'agents neuroprotecteurs
EP1204641A1 (fr) Derives 4-aminopiperidine de tetrahydronaphtalene, chromans et thiochromans
MXPA00006078A (en) 1,4-diazacycloheptane derivatives
EP1140863A1 (fr) Derives de 1,4-diazacycloheptane, utiles dans le traitement de troubles neurologiques
WO2000078751A2 (fr) Composes chimiques
WO2000039110A1 (fr) Derives homopiperazine en tant qu'inhibiteurs selectifs de l'emopamile
EP0544748A1 (fr) Spiro cycloalkylbenzene-1,1'-(1',2',3',4'-tetrahydroisoquinolines)] possedant des proprietes neuroprotectrices.
WO2002051793A1 (fr) Inhibiteurs de sterol isomerase

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20010806

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 20020214

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20020625